Urological Cancer Drugs Market Report

China Urological Cancer Drugs Industry Market Research Report 2023-2029

  • POSTDATE：Oct 05, 2023
  • PAGES：226
  • REPORT CODE：GMM1828446
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Urologic cancers include cancers of the bladder, kidney, prostate and testicles, all relatively common. Prostate cancer, for example, is the most common cancer in American men. One out of every 10 men will develop the disease at some time in his life — most often after age 50.

    This report elaborates on the current development of the Urological Cancer Drugs industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • GlaxoSmithKline

    • Johnson & Johnson

    • Abbott Laboratories

    • AstraZeneca

    • Pfizer

    • Roche Healthcare

    • Dendreon Corporation

    • Tolmar Inc

    • Astellas

    • Novartis

    • Ferring Pharmaceuticals

    • Celgene Corporation

    • Indevus Pharmaceuticals Inc

    By Type:

    • Xtandi (Enzalutamide)

    • Jevtana (Cabazitaxel)

    • Sutent (Sunitinib Malate)

    • Xofigo (Radium Ra 223 Dichloride)

    • Zytiga (Abiraterone Acetate)

    • Provenge (Sipuleucel-T)

    • Opdivo (Nivolumab)

    • Inlyta (Axitinib)

    • Votrient (Pazopanib Hydrochloride)

    By Application:

    • Testicular Cancer

    • Prostate Cancer

    • Bladder Cancer

    • Kidney Cancer

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Urological Cancer Drugs Market Overview 2018-2029

    • 1.1 China Urological Cancer Drugs Industry Development Overview

    • 1.2 China Urological Cancer Drugs Industry Development History

    • 1.3 China Urological Cancer Drugs Industry Market Size (2018-2029)

    • 1.4 China Urological Cancer Drugs Market Analysis by Type from Production Side

      • 1.4.1 China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Xtandi (Enzalutamide) (2018-2029)

      • 1.4.2 China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Jevtana (Cabazitaxel) (2018-2029)

      • 1.4.3 China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Sutent (Sunitinib Malate) (2018-2029)

      • 1.4.4 China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Xofigo (Radium Ra 223 Dichloride) (2018-2029)

      • 1.4.5 China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Zytiga (Abiraterone Acetate) (2018-2029)

      • 1.4.6 China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Provenge (Sipuleucel-T) (2018-2029)

      • 1.4.7 China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Opdivo (Nivolumab) (2018-2029)

      • 1.4.8 China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Inlyta (Axitinib) (2018-2029)

      • 1.4.9 China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Votrient (Pazopanib Hydrochloride) (2018-2029)

    • 1.5 China Urological Cancer Drugs Market Analysis by Application from Consumption End

      • 1.5.1 China Urological Cancer Drugs Sales Volume, Sales Value and Growth Rate of Testicular Cancer (2018-2029)

      • 1.5.2 China Urological Cancer Drugs Sales Volume, Sales Value and Growth Rate of Prostate Cancer (2018-2029)

      • 1.5.3 China Urological Cancer Drugs Sales Volume, Sales Value and Growth Rate of Bladder Cancer (2018-2029)

      • 1.5.4 China Urological Cancer Drugs Sales Volume, Sales Value and Growth Rate of Kidney Cancer (2018-2029)

    • 1.6 China Urological Cancer Drugs Market Analysis by Region

      • 1.6.1 North China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

    Chapter 2 China Urological Cancer Drugs Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Urological Cancer Drugs Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Urological Cancer Drugs Market Status and Competition Analysis in 2023

      • 2.2.3 China Urological Cancer Drugs Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Urological Cancer Drugs Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Urological Cancer Drugs Industry Development

    Chapter 3 Urological Cancer DrugsIndustry Chain Analysis

    • 3.1 Urological Cancer Drugs Industry Chain

    • 3.2 Urological Cancer Drugs Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Urological Cancer Drugs Market

    • 3.3 Urological Cancer Drugs Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Urological Cancer Drugs Market

    Chapter 4 China Urological Cancer Drugs Market, by Type

    • 4.1 China Urological Cancer Drugs Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Urological Cancer Drugs Total Production Volume and Growth Rate from Production Side

    • 4.5 China Urological Cancer Drugs Production Volume and Growth Rate, by Type

      • 4.5.1 China Urological Cancer Drugs Production Volume and Growth Rate of Xtandi (Enzalutamide)

      • 4.5.2 China Urological Cancer Drugs Production Volume and Growth Rate of Jevtana (Cabazitaxel)

      • 4.5.3 China Urological Cancer Drugs Production Volume and Growth Rate of Sutent (Sunitinib Malate)

      • 4.5.4 China Urological Cancer Drugs Production Volume and Growth Rate of Xofigo (Radium Ra 223 Dichloride)

      • 4.5.5 China Urological Cancer Drugs Production Volume and Growth Rate of Zytiga (Abiraterone Acetate)

      • 4.5.6 China Urological Cancer Drugs Production Volume and Growth Rate of Provenge (Sipuleucel-T)

      • 4.5.7 China Urological Cancer Drugs Production Volume and Growth Rate of Opdivo (Nivolumab)

      • 4.5.8 China Urological Cancer Drugs Production Volume and Growth Rate of Inlyta (Axitinib)

      • 4.5.9 China Urological Cancer Drugs Production Volume and Growth Rate of Votrient (Pazopanib Hydrochloride)

    Chapter 5 China Urological Cancer Drugs Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Urological Cancer Drugs Total Market Size and Growth Rate from Consumption End

    • 5.5 China Urological Cancer Drugs Market Size and Growth Rate, by Application

      • 5.5.1 China Urological Cancer Drugs Market Size and Growth Rate of Testicular Cancer

      • 5.5.2 China Urological Cancer Drugs Market Size and Growth Rate of Prostate Cancer

      • 5.5.3 China Urological Cancer Drugs Market Size and Growth Rate of Bladder Cancer

      • 5.5.4 China Urological Cancer Drugs Market Size and Growth Rate of Kidney Cancer

    Chapter 6 China Urological Cancer Drugs Market, by Region

    • 6.1 China Urological Cancer Drugs Production Volume and Production Value, by Region

    • 6.2 China Urological Cancer Drugs Sales Volume and Sales Value, by Region

    Chapter 7 North China Urological Cancer Drugs Market Analysis

    • 7.1 North China Urological Cancer Drugs Market, by Type

    • 7.2 North China Urological Cancer Drugs Market, by Application

    Chapter 8 Central China Urological Cancer Drugs Market Analysis

    • 8.1 Central China Urological Cancer Drugs Market, by Type

    • 8.2 Central China Urological Cancer Drugs Market, by Application

    Chapter 9 South China Urological Cancer Drugs Market Analysis

    • 9.1 South China Urological Cancer Drugs Market, by Type

    • 9.2 South China Urological Cancer Drugs Market, by Application

    Chapter 10 East China Urological Cancer Drugs Market Analysis

    • 10.1 East China Urological Cancer Drugs Market, by Type

    • 10.2 East China Urological Cancer Drugs Market, by Application

    Chapter 11 Northeast China Urological Cancer Drugs Market Analysis

    • 11.1 Northeast China Urological Cancer Drugs Market, by Type

    • 11.2 Northeast China Urological Cancer Drugs Market, by Application

    Chapter 12 Southwest China Urological Cancer Drugs Market Analysis

    • 12.1 Southwest China Urological Cancer Drugs Market, by Type

    • 12.2 Southwest China Urological Cancer Drugs Market, by Application

    Chapter 13 Northwest China Urological Cancer Drugs Market Analysis

    • 13.1 Northwest China Urological Cancer Drugs Market, by Type

    • 13.2 Northwest China Urological Cancer Drugs Market, by Application

    Chapter 14 Company Profiles

      • 14.1 GlaxoSmithKline

        • 14.1.1 GlaxoSmithKline Company Profile

        • 14.1.2 GlaxoSmithKline Urological Cancer Drugs Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Johnson & Johnson

        • 14.2.1 Johnson & Johnson Company Profile

        • 14.2.2 Johnson & Johnson Urological Cancer Drugs Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Abbott Laboratories

        • 14.3.1 Abbott Laboratories Company Profile

        • 14.3.2 Abbott Laboratories Urological Cancer Drugs Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 AstraZeneca

        • 14.4.1 AstraZeneca Company Profile

        • 14.4.2 AstraZeneca Urological Cancer Drugs Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Pfizer

        • 14.5.1 Pfizer Company Profile

        • 14.5.2 Pfizer Urological Cancer Drugs Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Roche Healthcare

        • 14.6.1 Roche Healthcare Company Profile

        • 14.6.2 Roche Healthcare Urological Cancer Drugs Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Dendreon Corporation

        • 14.7.1 Dendreon Corporation Company Profile

        • 14.7.2 Dendreon Corporation Urological Cancer Drugs Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Tolmar Inc

        • 14.8.1 Tolmar Inc Company Profile

        • 14.8.2 Tolmar Inc Urological Cancer Drugs Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Astellas

        • 14.9.1 Astellas Company Profile

        • 14.9.2 Astellas Urological Cancer Drugs Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 Novartis

        • 14.10.1 Novartis Company Profile

        • 14.10.2 Novartis Urological Cancer Drugs Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 Ferring Pharmaceuticals

        • 14.11.1 Ferring Pharmaceuticals Company Profile

        • 14.11.2 Ferring Pharmaceuticals Urological Cancer Drugs Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 Celgene Corporation

        • 14.12.1 Celgene Corporation Company Profile

        • 14.12.2 Celgene Corporation Urological Cancer Drugs Market Performance

        • 14.12.3 Product&Service Introduction

      • 14.13 Indevus Pharmaceuticals Inc

        • 14.13.1 Indevus Pharmaceuticals Inc Company Profile

        • 14.13.2 Indevus Pharmaceuticals Inc Urological Cancer Drugs Market Performance

        • 14.13.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Urological Cancer Drugs Industry Research Conclusions

    • 15.2 Urological Cancer Drugs Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Urological Cancer Drugs Industry Market Size (2018-2029)

    • Figure China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Xtandi (Enzalutamide) (2018-2029)

    • Figure China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Jevtana (Cabazitaxel) (2018-2029)

    • Figure China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Sutent (Sunitinib Malate) (2018-2029)

    • Figure China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Xofigo (Radium Ra 223 Dichloride) (2018-2029)

    • Figure China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Zytiga (Abiraterone Acetate) (2018-2029)

    • Figure China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Provenge (Sipuleucel-T) (2018-2029)

    • Figure China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Opdivo (Nivolumab) (2018-2029)

    • Figure China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Inlyta (Axitinib) (2018-2029)

    • Figure China Urological Cancer Drugs Production Volume, Production Value and Growth Rate of Votrient (Pazopanib Hydrochloride) (2018-2029)

    • Figure China Urological Cancer Drugs Sales Volume, Sales Value and Growth Rate of Testicular Cancer (2018-2029)

    • Figure China Urological Cancer Drugs Sales Volume, Sales Value and Growth Rate of Prostate Cancer (2018-2029)

    • Figure China Urological Cancer Drugs Sales Volume, Sales Value and Growth Rate of Bladder Cancer (2018-2029)

    • Figure China Urological Cancer Drugs Sales Volume, Sales Value and Growth Rate of Kidney Cancer (2018-2029)

    • Figure North China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Central China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure South China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure East China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Urological Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Urological Cancer Drugs Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Urological Cancer Drugs Market Share by Type in 2018

    • Figure China Urological Cancer Drugs Market Share by Type in 2023

    • Figure China Urological Cancer Drugs Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume and Growth Rate of Xtandi (Enzalutamide) (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume and Growth Rate of Jevtana (Cabazitaxel) (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume and Growth Rate of Sutent (Sunitinib Malate) (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume and Growth Rate of Xofigo (Radium Ra 223 Dichloride) (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume and Growth Rate of Zytiga (Abiraterone Acetate) (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume and Growth Rate of Provenge (Sipuleucel-T) (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume and Growth Rate of Opdivo (Nivolumab) (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume and Growth Rate of Inlyta (Axitinib) (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume and Growth Rate of Votrient (Pazopanib Hydrochloride) (2018-2023)

    • Figure China Urological Cancer Drugs Market Share by Application in 2018

    • Figure China Urological Cancer Drugs Market Share by Application in 2023

    • Figure China Urological Cancer Drugs Total Market Size and Growth Rate from Consumption End

    • Figure China Urological Cancer Drugs Market Size and Growth Rate of Testicular Cancer (2018-2023)

    • Figure China Urological Cancer Drugs Market Size and Growth Rate of Prostate Cancer (2018-2023)

    • Figure China Urological Cancer Drugs Market Size and Growth Rate of Bladder Cancer (2018-2023)

    • Figure China Urological Cancer Drugs Market Size and Growth Rate of Kidney Cancer (2018-2023)

    • Table China Urological Cancer Drugs Production Volume by Region (2018-2023)

    • Table China Urological Cancer Drugs Production Volume Share by Region (2018-2023)

    • Figure China Urological Cancer Drugs Production Volume Share by Region (2018-2023)

    • Table China Urological Cancer Drugs Production Value by Region (2018-2023)

    • Table China Urological Cancer Drugs Production Value Share by Region (2018-2023)

    • Figure China Urological Cancer Drugs Production Value Share by Region (2018-2023)

    • Table China Urological Cancer Drugs Sales Volume by Region (2018-2023)

    • Table China Urological Cancer Drugs Sales Volume Share by Region (2018-2023)

    • Figure China Urological Cancer Drugs Sales Volume Share by Region (2018-2023)

    • Table China Urological Cancer Drugs Sales Value by Region (2018-2023)

    • Table China Urological Cancer Drugs Sales Value Share by Region (2018-2023)

    • Figure China Urological Cancer Drugs Sales Value Share by Region (2018-2023)

    • Table North China Urological Cancer Drugs Production Volume by Type (2018-2023)

    • Table North China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure North China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table North China Urological Cancer Drugs Sales Volume by Application (2018-2023)

    • Table North China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure North China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table Central China Urological Cancer Drugs Production Volume by Type (2018-2023)

    • Table Central China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure Central China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table Central China Urological Cancer Drugs Sales Volume by Application (2018-2023)

    • Table Central China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure Central China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table South China Urological Cancer Drugs Production Volume by Type (2018-2023)

    • Table South China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure South China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table South China Urological Cancer Drugs Sales Volume by Application (2018-2023)

    • Table South China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure South China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table East China Urological Cancer Drugs Production Volume by Type (2018-2023)

    • Table East China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure East China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table East China Urological Cancer Drugs Sales Volume by Application (2018-2023)

    • Table East China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure East China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table Northeast China Urological Cancer Drugs Production Volume by Type (2018-2023)

    • Table Northeast China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure Northeast China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table Northeast China Urological Cancer Drugs Sales Volume by Application (2018-2023)

    • Table Northeast China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table Southwest China Urological Cancer Drugs Production Volume by Type (2018-2023)

    • Table Southwest China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure Southwest China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table Southwest China Urological Cancer Drugs Sales Volume by Application (2018-2023)

    • Table Southwest China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table Northwest China Urological Cancer Drugs Production Volume by Type (2018-2023)

    • Table Northwest China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure Northwest China Urological Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table Northwest China Urological Cancer Drugs Sales Volume by Application (2018-2023)

    • Table Northwest China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Urological Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table GlaxoSmithKline Company Profile

    • Table GlaxoSmithKline Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Johnson & Johnson Company Profile

    • Table Johnson & Johnson Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Abbott Laboratories Company Profile

    • Table Abbott Laboratories Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table AstraZeneca Company Profile

    • Table AstraZeneca Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Pfizer Company Profile

    • Table Pfizer Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Roche Healthcare Company Profile

    • Table Roche Healthcare Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Dendreon Corporation Company Profile

    • Table Dendreon Corporation Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Tolmar Inc Company Profile

    • Table Tolmar Inc Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Astellas Company Profile

    • Table Astellas Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Novartis Company Profile

    • Table Novartis Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Ferring Pharmaceuticals Company Profile

    • Table Ferring Pharmaceuticals Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Celgene Corporation Company Profile

    • Table Celgene Corporation Urological Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Indevus Pharmaceuticals Inc Company Profile

    • Table Indevus Pharmaceuticals Inc Urological Cancer Drugs Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US